Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer

Clinical Oncology and Research
doi 10.31487/j.cor.2020.02.08
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Science Repository OU

Related search

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

E3 Ubiquitin Ligases CBL-B and C-CBL Downregulate PD-L1 in EGFR Wild-Type Non-Small Cell Lung Cancer

FEBS Letters
GeneticsCell BiologyMolecular BiologyBiochemistryStructural BiologyBiophysics
2018English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy